<DOC>
	<DOC>NCT01942590</DOC>
	<brief_summary>Funding Source- FDA OOPD The purpose of this study is to investigate the safety and efficacy of clenbuterol on motor function in individuals with late-onset Pompe disease (LOPD) who are treated with enzyme replacement therapy (ERT).</brief_summary>
	<brief_title>Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Clenbuterol</mesh_term>
	<criteria>1. Diagnosis of Pompe disease by blood acid alphaglucosidase assay and acid alphaglucosidase gene sequencing, 2. Age: 18+ years at enrollment, 3. Receiving ERT at standard dose (20 mg/kg every 2 weeks) for at least 52 weeks, 4. Subjects are capable of giving written consent. 1. Continuous invasive ventilation (via tracheostomy or endotracheal tube) 2. Clinically relevant illness within two weeks of enrollment including fever &gt; 38.2 C, vomiting more than once in 24 hours, seizure, or other symptom deemed contraindicative to new therapy. 3. Chronic heart disease (Myocardial infarction, arrythmia, cardiomyopathy) 4. Tachycardia 5. History of seizure disorder 6. Hyperthyroidism 7. Pheochromocytoma 8. Pregnancy 9. History of diabetes 10. History of hypersensitivity to beta 2agonist drugs such as albuterol, levalbuterol (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline, salmeterol (Serevent), 11. Patients on a nonstandard schedule for ERT; for example, weekly infusions as opposed to infusions every two weeks. 12. Treatment for asthma in the previous 12 months. 13. The use of the following concommitant meds is prohibited during the study: diuretics (water pill); digoxin (digitalis, Lanoxin); betablockers such as atenolol (Tenormin), metoprolol (Lopressor), and propranolol (Inderal); tricyclic antidepressants such as amitriptyline (Elavil, Etrafon), doxepin (Sinequan), imipramine (Janimine, Tofranil), and nortriptyline (Pamelor); Monoamine oxidase inhibitors such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate); or other bronchodilators such as albuterol, levalbuterol (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline (Brethine, Bricanyl), salmeterol (Serevent), isoetherine (Bronkometer), metaproterenol (Alupent, Metaprel), or isoproterenol (Isuprel Mistometer).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pompe disease</keyword>
</DOC>